ARCH’s Bob Nelsen on launching Xaira with $1B+ to reinvent drug discovery with AI – Endpoints News

In the 37 years since co-found­ing ARCH Ven­ture Part­ners, Bob Nelsen has built a rep­u­ta­tion for plac­ing head-turn­ing bets on ideas that car­ry huge amounts of risk and re­ward.

His lat­est — on AI start­up Xaira Ther­a­peu­tics — is both the biggest bet of his ca­reer and in ARCH’s his­to­ry for a new com­pa­ny. Xaira is launch­ing with over $1 bil­lion in com­mit­ted cap­i­tal, End­points News ex­clu­sive­ly re­port­ed Tues­day, and ARCH will con­tribute over $200 mil­lion, Nelsen said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.